Mereo BioPharma Files 8-K on Operations and Financials
Ticker: MREO · Form: 8-K · Filed: Aug 12, 2025 · CIK: 1719714
| Field | Detail |
|---|---|
| Company | Mereo Biopharma Group PLC (MREO) |
| Form Type | 8-K |
| Filed Date | Aug 12, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, financials
TL;DR
Mereo BioPharma dropped an 8-K on financials & ops - check it for the latest.
AI Summary
Mereo BioPharma Group plc filed an 8-K on August 12, 2025, reporting on its results of operations and financial condition, as well as filing financial statements and exhibits. The filing does not contain specific financial figures or operational details within the provided text, but indicates a standard reporting event for the company.
Why It Matters
This filing serves as an official update on Mereo BioPharma's operational and financial status, which is crucial for investors to assess the company's performance and outlook.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of operational and financial information, not indicating any immediate or significant risks.
Key Players & Entities
- Mereo BioPharma Group plc (company) — Registrant
- August 12, 2025 (date) — Date of earliest event reported
FAQ
What specific financial results or operational updates are detailed in this 8-K filing?
The provided text indicates the filing pertains to 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits,' but does not include specific figures or details within this excerpt.
What is the filing date for this 8-K report?
The filing date, and the date of the earliest event reported, is August 12, 2025.
What is the company's primary industry classification?
Mereo BioPharma Group plc is classified under 'PHARMACEUTICAL PREPARATIONS [2834]'.
Where is Mereo BioPharma Group plc incorporated?
The company is incorporated in England and Wales.
What is the SEC file number for Mereo BioPharma Group plc?
The SEC file number is 001-38452.
Filing Stats: 565 words · 2 min read · ~2 pages · Grade level 11.8 · Accepted 2025-08-12 07:40:38
Filing Documents
- mreo-20250812.htm (8-K) — 53KB
- mreo-ex99_1.htm (EX-99.1) — 275KB
- 0000950170-25-106924.txt ( ) — 496KB
- mreo-20250812.xsd (EX-101.SCH) — 57KB
- mreo-20250812_htm.xml (XML) — 6KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On August 12, 2025, Mereo BioPharma Group plc announced its financial results for the second quarter ended June 30, 2025 and provided recent corporate highlights. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in Item 2.02 of this Form 8-K (including Exhibit 99.1 attached hereto) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description of Exhibit 99.1 Press Release, dated August 12, 2025 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. MEREO BIOPHARMA GROUP PLC Date: August 12, 2025 By: /s/ Christine Fox Name: Christine Fox Title: Chief Financial Officer